Zobrazeno 101 - 110
of 185
pro vyhledávání: ''
Autor:
Lauren M. Zasadil, Mark E. Burkard, Beth A. Weaver, Jennifer Laffin, Ryan A. Denu, Craig Kanugh
Publikováno v:
BMC Cancer
Background Centrosome amplification (CA) has been reported in nearly all types of human cancer and is associated with deleterious clinical factors such as higher grade and stage. However, previous reports have not shown how CA affects cellular differ
Autor:
Feng Xu, Lu-Xi Song, Zheng Zhang, Liyu Zhou, Qi He, Chunkang Chang, Lingyun Wu, Chao Xiao, Jiying Su, Wen-Hui Shi, Dong Wu, Xiao Li
Publikováno v:
Journal of Translational Medicine
Background Despite the efficacy of decitabine treatment in myelodysplastic syndrome (MDS), no definite predictor of response is known. In this study, we investigated whether the expression levels of human equilibrative nucleoside transporter 1 (hENT1
Publikováno v:
BMC Cancer
Background The predictive accuracy of the American Joint Committee on Cancer (AJCC) stages of colorectal cancer (CRC) is mediocre. This study aimed to develop postoperative nomograms to predict cancer-specific survival (CSS) and overall survival (OS)
Autor:
Katsuyuki Karasawa, Keiichi Jingu, Tetsuo Nishimura, Yoshiyuki Shioyama, Yuzuru Niibe, Hiroki Shirato, Tetsuya Inoue
Publikováno v:
BMC Cancer
Background: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT). Methods: Patients t
Autor:
Izuma Nakayama, Kensei Yamaguchi, Takeru Wakatsuki, Tomohiro Matsushima, Takashi Ichimura, Nobuyuki Mizunuma, Keisho Chin, Mariko Ogura, Daisuke Takahari, Mitsukuni Suenaga, Masato Ozaka, Eiji Shinozaki
Publikováno v:
BMC Cancer
Background After analysis of minor RAS mutations (KRAS exon 3, 4/NRAS) in the FIRE-3 and PRIME studies, an expanded range of RAS mutations were established as a negative predictive marker for the efficacy of anti-EGFR antibody treatment. BRAF and PIK
Publikováno v:
BMC Cancer
Background Changes in the number of alleles of a chromosome may have an impact upon gene expression. Loss of heterozygosity (LOH) indicates that one allele of a gene has been lost, and knowing the exact copy number of the gene would indicate whether
Publikováno v:
BMC Cancer
Background Angiogenesis is generally involved during the cancer development and hematogenous metastasis. Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) are considered to have an important role in tumor-associate
Autor:
Lei Jiang, Qiang Qiang, Qiubei Zhu, Ying Jiang, Guohan Hu, Hua He, Xuehua Ding, Chenran Zhang, Liuhua Hu, Yicheng Lu
Publikováno v:
BMC Cancer
Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) displays strong tumor suppressive activities, and its expression is often silenced in many types of human tumors. However, the relationship between RIZ1 expression and glioma prognosis rema
Autor:
Yun Lian, Yaoyu Chen, Si-Xuan Qian, Jiayu Huang, Yue Xie, Yanru Li, Jianping Mao, Shuai Wang, Jianyong Li, Huihui Zhao, Yu Zhu, Ming Hong
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-13 (2016)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Cancer cells show increased glycolysis and take advantage of this metabolic pathway to generate ATP. The TP53-induced glycolysis and apoptosis regulator (TIGAR) inhibits aerobic glycolysis and protects tumor cells from intracellular reacti
Autor:
Seock-Ah Im, Kyung Hun Lee, Dong Young Noh, Sae-Won Han, Han Suk Ryu, Tae Yong Kim, Wonshik Han, Hyeong-Gon Moon, Do Youn Oh, Koung Jin Suh, Tae-You Kim, Yaewon Yang, Bhumsuk Keam, In Ae Park
Publikováno v:
BMC CANCER(16)
BMC Cancer
BMC Cancer
Background: Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6-8 cycles of NAC has become the standard regimen to improve the ou